GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Beta Bionics Inc
The private market value of Beta Bionics, the developer of the "bionic pancreas," is determined by the revolutionary potential of its iLet device. The potential post-IPO share price will reflect commercialization success and the potential to change the standard of care for type 1 diabetes.
Share prices of companies in the market segment - Specialized medical equipment
The value of Beta Bionics, the developer of the iLet "bionic pancreas," is determined by its ability to commercialize this breakthrough technology. We classify it in the Specialized Medical Equipment sector, and the chart below reflects the dynamics of the entire diabetes treatment segment, driven by innovation.
Broad Market Index - GURU.Markets
Beta Bionics is a medical technology company that developed iLet, the world's first fully automated insulin dosing system (a "bionic pancreas"). As part of the GURU.Markets index, it is revolutionizing diabetes treatment. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
BBNX - Daily change in the company's share price Beta Bionics Inc
For Beta Bionics, a manufacturer of automated insulin pumps, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to product news. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in medical technology.
Daily change in the price of a set of shares in a market segment - Specialized medical equipment
The medical device sector in which Beta Bionics Inc operates is highly dynamic. This chart reflects the average volatility of the industry. It serves as a benchmark for assessing how sensitive Beta Bionics' artificial pancreas business is to overall trends.
Daily change in the price of a broad market stock, index - GURU.Markets
Beta Bionics is a privately held medical technology company that developed the iLet bionic pancreas. Its potential IPO will depend heavily on the market's appetite for medical technology innovation. The chart below shows the general volatility that influences the fate of such "unicorns."
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Beta Bionics Inc
Beta Bionics is a medical technology company. Its success depends on its ability to commercialize its unique developments. Shares of such small, innovative companies often experience high volatility.
Annual dynamics of market capitalization of the market segment - Specialized medical equipment
Beta Bionics, a privately held company, is developing a revolutionary "bionic pancreas." Its growth, as demonstrated by its funding rounds, is likely significantly outpacing the medical device sector, reflecting the enormous potential of its technology to completely automate the treatment of type 1 diabetes.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Beta Bionics is privately held and not publicly traded. Its market performance cannot be analyzed. As the developer of a bionic pancreas, its business is at the forefront of medical technology. Its success is determined by clinical data and its ability to bring the product to market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Beta Bionics Inc
Beta Bionics's valuation as the developer of the "bionic pancreas" would depend on medical breakthroughs. Monthly fluctuations would reflect progress in clinical trials and regulatory approvals for its automated insulin delivery system.
Monthly dynamics of market capitalization of the market segment - Specialized medical equipment
The diabetes technology market is one of the fastest-growing in healthcare. The chart below reflects investor enthusiasm for innovative devices that improve patients' lives. Riding this wave, companies like Beta Bionics are developing automated glucose monitoring systems.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Beta Bionics, the developer of the "bionic pancreas," is an innovative medical technology company. Its shares thrive on product news, regulatory approvals, and commercial success. Their performance is largely independent of overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Beta Bionics Inc
Shares of Beta Bionics, the developer of an automated insulin delivery system (the "bionic pancreas"), experience high volatility on a weekly basis. News of FDA approval, real-world patient data, and comparisons with competitors are driving sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Specialized medical equipment
Beta Bionics shares, like the entire diabetes medical technology sector, are moving against a backdrop of innovation and competition. Breakthroughs in automated glucose monitoring are driving the company. The chart below shows how the company stacks up against leaders like DexCom and Insulet.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Beta Bionics shares, like other speculative biotechs, live in a world of their own, driven by FDA news and clinical data. Their performance is largely unrelated to overall market trends, except during periods of panic when investors dump all risky assets.
Market capitalization of the company, segment and market as a whole
BBNX - Market capitalization of the company Beta Bionics Inc
Beta Bionics' market capitalization chart is a visualization of the hopes for a fully automated "artificial pancreas." It reflects investor valuation of its iLet system, which simplifies glucose monitoring for people with type 1 diabetes. Its dynamics tell the story of how the market weighs the technology's revolutionary potential against the challenges of commercialization.
BBNX - Share of the company's market capitalization Beta Bionics Inc within the market segment - Specialized medical equipment
Beta Bionics is developing the iLet "bionic pancreas"—an innovative automated insulin pump. Its market share in diabetes care reflects the potential of this breakthrough technology. The graph shows how its device can transform patients' lives by simplifying blood sugar management.
Market capitalization of the market segment - Specialized medical equipment
Beta Bionics is developing a bionic pancreas—an innovative device for people with type 1 diabetes. The chart below shows the overall value of the specialized medical equipment sector. Its growth reflects the hopes for technologies capable of dramatically improving quality of life, which is precisely what Beta Bionics is doing.
Market capitalization of all companies included in a broad market index - GURU.Markets
The medical technologies visible in the graph have the potential to change patients' lives. Beta Bionics is developing a "bionic pancreas"—a fully automated system for people with type 1 diabetes. Its capitalization represents a risky bet on a revolutionary technology that could become a new standard of care.
Book value capitalization of the company, segment and market as a whole
BBNX - Book value capitalization of the company Beta Bionics Inc
Beta Bionics' book value represents the physical embodiment of the "bionic pancreas." The chart shows investments in the development and production of iLet, the world's first fully automated insulin dosing system. These are tangible assets that are changing the lives of people with type 1 diabetes.
BBNX - Share of the company's book capitalization Beta Bionics Inc within the market segment - Specialized medical equipment
Beta Bionics, a diabetes technology company, is building its manufacturing base. Its stake in the sector reflects investments in creating production facilities for its bihormonal artificial pancreas. This provides the physical foundation for bringing this innovative product to market.
Market segment balance sheet capitalization - Specialized medical equipment
Beta Bionics is a medical technology company. This sector, as the chart shows, is capital-intensive. Beta Bionics has developed a unique product—an automatic insulin pump—and its capital is invested in the R&D and production of this complex device.
Book value of all companies included in the broad market index - GURU.Markets
Beta Bionics is developing a "bionic pancreas"—a wearable device for automated glucose monitoring. The company's book value reflects its investment in R&D, clinical trials, and manufacturing capacity for this breakthrough medical device.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Beta Bionics Inc
Beta Bionics is a medical technology company. Its entire market capitalization is a premium to its modest assets, betting on its revolutionary iLet device—a "bionic pancreas" that could change the lives of people with diabetes.
Market to book capitalization ratio in a market segment - Specialized medical equipment
Beta Bionics is developing a bionic pancreas prosthesis for automatic glucose monitoring. This is a breakthrough technology in diabetes treatment. The chart shows the enormous premium the market places on its intellectual property and the potential to change the lives of millions of people, compared to its modest tangible assets.
Market to book capitalization ratio for the market as a whole
Beta Bionics is a medical technology company that developed the world's first fully automated "artificial pancreas" system for people with type 1 diabetes. Compared to average market valuations, as shown in this chart, its high premium is based on the revolutionary potential of its technology to improve the lives of millions of people.
Debts of the company, segment and market as a whole
BBNX - Company debts Beta Bionics Inc
Beta Bionics is a medical technology company developing a bionic pancreas for people with diabetes. During the development and commercialization phases, the company incurs significant expenses on research, clinical trials, and marketing. This chart shows how capital, including debt, is being used to bring this life-saving technology to market.
Market segment debts - Specialized medical equipment
Beta Bionics is a medical company developing a bionic pancreas for people with type 1 diabetes. While commercializing its product, the company incurs significant costs for production, marketing, and further research. This chart illustrates the financial strategy it is using to bring its innovative technology to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Beta Bionics Inc
Beta Bionics is developing a medical device—a bionic pancreas. This chart shows how the company finances its expensive research and development. For a medical technology company at the commercialization stage, debt load is a risk indicator: will it be able to generate sufficient revenue to service its debt before running out of funds?
Market segment debt to market segment book capitalization - Specialized medical equipment
Beta Bionics is developing a bionic pancreatic prosthesis—an innovative device for people with type 1 diabetes. Developing such complex medical equipment requires enormous investment. This chart shows the sector's collective debt load, which helps understand how the company finances its expensive clinical trials and research compared to its competitors.
Debt to book value of all companies in the market
Beta Bionics Inc. is a medical company developing a bionic pancreas prosthesis. During the product's market launch, it requires significant funds for production and marketing. This chart illustrates the overall availability of capital, which influences Beta Bionics' choice between diluting investor stakes and raising potentially risky debt financing.
P/E of the company, segment and market as a whole
P/E - Beta Bionics Inc
This metric for Beta Bionics, the developer of the "bionic pancreas," reflects enormous expectations. As a medical company on the cusp of commercialization, its P/E (if any) will be very high. Investors are betting that its device will revolutionize diabetes treatment and capture a huge market.
P/E of the market segment - Specialized medical equipment
Beta Bionics is a medical technology company developing the iLet bionic pancreas, a wearable device that automatically monitors blood sugar levels and doses insulin. This chart shows the average valuation for the medical device sector. It helps estimate the market premium for this potentially revolutionary diabetes device.
P/E of the market as a whole
Beta Bionics (privately held, ticker symbol BBNX may be misleading) is a medical technology company developing the iLet "bionic pancreas" for automated glucose management in diabetics. Its valuation is a bet on a revolution in diabetes treatment. It is not dependent on general economic cycles, but is determined by the success of its technology and regulatory decisions.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Beta Bionics Inc
Beta Bionics is a medical technology company developing a bi-hormonal "bionic pancreas" for automated blood sugar monitoring in people with type 1 diabetes. Its valuation is based on the future success of this technology. This chart reflects the investors' belief in the device's commercial potential and its ability to transform patients' lives.
%20P%2FE%20Beta%20Bionics%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Beta-Bionics-Inc&v=1772681279492 "Chart of the company's future (projected) P/E Beta Bionics Inc")
Future (projected) P/E of the market segment - Specialized medical equipment
Beta Bionics is a medical technology company developing the iLet bionic pancreas for automated management of type 1 diabetes. The chart reflects average profitability expectations in the medical device sector. BBNX's position relative to this benchmark reflects investors' bet that their revolutionary device will transform the lives of diabetics and conquer the market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-medical-equipment&v=1772681279520 "Future (projected) P/E graph of the market segment - Specialized medical equipment")
Future (projected) P/E of the market as a whole
Beta Bionics is developing a bionic pancreas for people with type 1 diabetes. Like many medical startups, its valuation is based on future potential. This chart illustrates the general risk appetite. During periods when the market is willing to pay for innovation, breakthrough medical technologies receive higher valuations and access to capital.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772681279558 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Beta Bionics Inc
Beta Bionics is a medical technology company developing the iLet bionic pancreas for automated glucose management in people with type 1 diabetes. The chart shows the company's financial performance at the commercialization stage; profit depends on the successful launch of the system and sales volumes.
Profit of companies in the market segment - Specialized medical equipment
Beta Bionics is developing a bionic pancreatic prosthesis—an innovative device for people with type 1 diabetes. The company's success depends on clinical trials, regulatory approval, and technology implementation. The graph shows the collective profitability of the specialized medical equipment sector, illustrating the industry's success in commercializing breakthrough medical technologies.
Overall market profit
Beta Bionics is developing a bionic pancreas prosthesis—a breakthrough device for diabetics. The company's success depends on investment in R&D and the willingness of healthcare systems to pay for expensive technologies. The growth in overall market revenue, as shown in the graph, creates a favorable climate for venture capital financing and the implementation of medical innovations, which is critical for Beta Bionics.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Beta Bionics Inc
Beta Bionics is developing a bionic pancreas—an innovative device for automated glucose management in people with type 1 diabetes. Future revenue depends on regulatory approval and commercialization. This chart shows analyst expectations for the successful commercialization of this breakthrough medical device.
%20profit%20of%20the%20company%20Beta%20Bionics%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Beta-Bionics-Inc&v=1772681279613 "Graph of future (projected) profit of the company Beta Bionics Inc")
Future (predicted) profit of companies in the market segment - Specialized medical equipment
Beta Bionics is developing a bionic pancreas—an innovative device for automated glucose monitoring in people with type 1 diabetes. The company's success depends on trial results and regulatory approval. This chart shows profitability forecasts for the medical device sector, allowing one to assess the potential of Beta Bionics' breakthrough technology against the broader industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-medical-equipment&v=1772681279637 "Graph of future (predicted) profits of companies in a market segment - Specialized medical equipment")
Future (predicted) profit of the market as a whole
Beta Bionics is a medical company developing a bionic pancreas for people with type 1 diabetes. Its success depends on clinical trial results, regulatory approval, and market acceptance of the technology, rather than on general economic cycles. This corporate earnings curve has virtually no impact on its operating performance.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772681279653 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Beta Bionics Inc
Beta Bionics is a medical technology company developing a bionic pancreas for people with type 1 diabetes. With minimal current revenue, this chart shows the enormous expectations of investors. The fluctuations reflect news about clinical trials and regulatory approvals for its breakthrough device.
P/S market segment - Specialized medical equipment
Beta Bionics is a medical device company developing a bionic pancreas to automatically manage glucose levels in people with type 1 diabetes. Future revenue depends on the commercialization of this device. This chart for the medical device sector compares investor expectations for Beta Bionics' revolutionary technology with those of other innovative companies.
P/S of the market as a whole
Beta Bionics is a medical technology company developing the iLet bionic pancreas for automated glucose management in people with type 1 diabetes. The company's revenue depends on the successful commercialization of this innovative device. This revenue valuation chart helps understand how high investor expectations are for this breakthrough technology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Beta Bionics Inc
Beta Bionics is a medical technology company developing a bionic pancreas to automatically manage glucose levels in people with type 1 diabetes. This chart shows how the market views the future sales of this revolutionary device. It reflects investor expectations regarding the product's commercial success and its clinical implementation.
%20P%2FS%20Beta%20Bionics%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Beta-Bionics-Inc&v=1772681279721 "The graph of the company's future (projected) P/S Beta Bionics Inc")
Future (projected) P/S of the market segment - Specialized medical equipment
Beta Bionics is a medical technology company that developed the iLet Bionic Pancreas, the world's first fully automated insulin dosing system. The company's valuation reflects its high hopes that its device will revolutionize the treatment of type 1 diabetes, significantly simplifying patients' lives, creating significant market potential.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-medical-equipment&v=1772681279791 "Future (projected) P/S market segment graph - Specialized medical equipment")
Future (projected) P/S of the market as a whole
Beta Bionics Inc. is developing a bionic pancreas prosthesis for automatic glucose monitoring. This is a breakthrough technology in diabetes treatment. Revenue growth projections reflected here may be dramatically impacted by similar medical innovations in the future.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772681279828 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Beta Bionics Inc
Beta Bionics is a medical technology company that developed the iLet bionic pancreas. This chart shows revenue from sales of this automated insulin dosing system, designed to simplify the management of type 1 diabetes. Sales growth depends on patient and physician acceptance of the system, as well as insurance coverage.
Sales of companies in the market segment - Specialized medical equipment
Beta Bionics (BBNX) has developed the iLet Bionic Pancreas, the world's first fully automated insulin delivery system. The device uses algorithms to self-monitor glucose levels in diabetics. This figure reflects the revenues of the medical device market, where Beta Bionics' breakthrough technology has the potential to radically change the lives of millions of people with type 1 diabetes.
Overall market sales
Beta Bionics is developing a bionic pancreas prosthesis to automatically manage glucose levels in people with type 1 diabetes. While demand for its products is driven by medical needs, the overall economic situation, as reflected in the graph, impacts accessibility. Economic growth facilitates better insurance coverage and healthcare financing.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Beta Bionics Inc
Beta Bionics is developing and commercializing the iLet bionic pancreas, a wearable medical device for people with type 1 diabetes. The company's future revenue depends on the successful launch of the product and its acceptance by patients. This chart reflects analyst sales forecasts, which assess the potential of this revolutionary technology in diabetes treatment.
%20sales%20of%20the%20company%20Beta%20Bionics%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Beta-Bionics-Inc&v=1772681279903 "Schedule of future (projected) sales of the company Beta Bionics Inc")
Future (projected) sales of companies in the market segment - Specialized medical equipment
Beta Bionics is a medical technology company that developed the world's first fully automated insulin delivery system (the "bionic pancreas"). This graph shows the potential revenue from sales of their iLet system. This is an analyst's view of the commercial prospects for this breakthrough technology for the treatment of type 1 diabetes.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-medical-equipment&v=1772681279919 "Schedule of future (projected) sales of companies in the market segment - Specialized medical equipment")
Future (projected) sales of the market as a whole
Beta Bionics is a medical technology company that has developed the world's first fully automated bionic pancreas for people with type 1 diabetes. Its success depends on the adoption of this technology. This schedule, reflecting the state of the economy, affects the budgets of insurance companies and healthcare systems, which determine the speed of adoption of such innovations.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772681279929 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Beta Bionics Inc
Beta Bionics is developing a bionic pancreas—an innovative device for automated glucose management in people with type 1 diabetes. Current financial performance reflects active investment in clinical trials and product launch. The chart illustrates current profitability, which is targeted for future growth after commercialization.
Market segment marginality - Specialized medical equipment
Beta Bionics is a medical technology company developing the iLet bionic pancreas, which automatically regulates glucose levels in people with type 1 diabetes. This chart shows its path to profitability. Improvement in this indicator will indicate a successful product launch and increased patient adoption.
Market marginality as a whole
Beta Bionics is developing a biohormonal "bionic pancreas" for people with type 1 diabetes. The company's success depends on the ability of healthcare systems to finance such cutting-edge technologies. This chart, which reflects overall economic health, indirectly indicates the solvency of insurance companies and government programs that support the product's implementation.
Employees in the company, segment and market as a whole
Number of employees in the company Beta Bionics Inc
Beta Bionics is a medical technology company developing a "bionic pancreas" for automated insulin delivery. The team's growth is critical and reflects progress in clinical trials, regulatory approvals, and preparations for the commercial launch of this revolutionary product.
Share of the company's employees Beta Bionics Inc within the market segment - Specialized medical equipment
Beta Bionics is a medical technology company developing a "bionic pancreas" for people with type 1 diabetes. Creating such a complex device requires a large team of engineers, scientists, and clinicians. This graph illustrates the amount of human intellect and effort invested in this innovative, life-changing technology.
Number of employees in the market segment - Specialized medical equipment
Beta Bionics is developing a bionic pancreas for people with type 1 diabetes. The employment dynamics in the specialized medical device sector, shown here, reflect the pace of innovation in MedTech. Growth in this sector means Beta Bionics operates in a rapidly evolving environment where competition for engineers and clinical specialists is intense.
Number of employees in the market as a whole
Beta Bionics is a company developing a bionic pancreas. Its growth is driven by innovation and clinical implementation, not economic cycles. Its highly specialized team of engineers and scientists is a key part of the cutting-edge medical technology sector within the broader economy, illustrated here.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Beta Bionics Inc (BBNX)
Beta Bionics is the medical company that developed iLet, the world's first fully automated glucose monitoring system (the "bionic pancreas"). The company's entire capital is its revolutionary technology. This figure demonstrates the enormous value the market places on this breakthrough product, created by a small team of engineers and scientists.
%20of%20the%20company%20Beta%20Bionics%20Inc%20(BBNX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Beta-Bionics-Inc-BBNX&v=1772681280312 "Chart of market capitalization per employee (in thousands of dollars) of the company Beta Bionics Inc (BBNX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized medical equipment
Beta Bionics is developing a biohormonal "bionic pancreas" for diabetics. This is a breakthrough medical technology. The company's high market capitalization per employee reflects the market's high expectations for this innovative product. The chart shows the future value investors are placing on the work of each engineer and scientist at the company.
%20by%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-medical-equipment&v=1772681280343 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
Beta Bionics is developing a biohormonal "bionic pancreas" for people with type 1 diabetes. The chart illustrates the market valuation of this cutting-edge medical development. The company's entire value is derived from the potential of its device. This metric demonstrates the enormous value investors place on the work of each member of the engineering and scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772681280367 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Beta Bionics Inc (BBNX)
Beta Bionics is a medical company developing a bionic pancreas (iLet) for automated diabetes management. At the product launch stage, this metric may be low or negative, reflecting investments in production and marketing. In the future, it will demonstrate how effectively the company scales sales and production of this complex device.
%20Chart%20Beta%20Bionics%20Inc%20(BBNX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Beta-Bionics-Inc-BBNX&v=1772681280440 "Company Profit Per Employee (in thousands of dollars) Chart Beta Bionics Inc (BBNX)")
Profit per employee (in thousands of dollars) in the market segment - Specialized medical equipment
Beta Bionics is a medical technology company that has developed the "bionic pancreas" (iLet), an automated insulin delivery system. At the commercialization stage, this metric reflects the balance between R&D and production costs and growing revenue from sales of an innovative device that changes the lives of people with diabetes.
%20in%20the%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-medical-equipment&v=1772681280463 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
Beta Bionics is a medical device company that developed the "bionic pancreas" (iLet), an automated insulin delivery system for diabetics. This is a breakthrough product in MedTech. The business is based on complex technologies (algorithms) and patents. This chart helps us understand that in the innovative medical device sector, profit per employee can be very high, as the value lies in the device itself, not in mass labor.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772681280472 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Beta Bionics Inc (BBNX)
Beta Bionics is a medical technology company developing the iLet bionic pancreas for people with type 1 diabetes. In the early commercialization stage, revenue per employee reflects the speed of market adoption of this innovative system. This chart tracks sales growth and how this breakthrough technology is beginning to transform patients' lives.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Beta-Bionics-Inc-BBNX&v=1772681280487 "Sales chart per company employee Beta Bionics Inc (BBNX)")
Sales per employee in the market segment - Specialized medical equipment
Beta Bionics (BBNX) is the developer of the iLet, a "bionic pancreas" for automated diabetes management. This metric reflects the average revenue per employee in the medical equipment segment. It helps assess how effectively BBNX utilizes its staff to promote and sell this innovative system compared to competitors.
Sales per employee for the market as a whole
Beta Bionics (BBNX) is a medical technology company that has developed the "bionic pancreas" (iLet), an automated insulin delivery system. This is a breakthrough technology. This metric is critical during the product launch phase. It demonstrates how successfully the company is growing sales of its high-tech device, leveraging its engineering, manufacturing, and commercialization teams.
Short shares by company, segment and market as a whole
Shares shorted by company Beta Bionics Inc (BBNX)
Beta Bionics (BBNX) is a medical technology company that has developed a bionic pancreas (iLet) for automated management of type 1 diabetes. It's a potentially revolutionary product. This chart shows the level of bearish bets. A high value may indicate the market is wary of fierce competition from giants (Medtronic, Tandem) or is unsure about the speed of commercialization of iLet. (347)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Beta-Bionics-Inc-BBNX&v=1772681280519 "Short Shares Chart for the Company Beta Bionics Inc (BBNX)")
Shares shorted by market segment - Specialized medical equipment
Beta Bionics is developing the "bionic pancreas" (iLet), a fully automated insulin delivery system for type 1 diabetics. This chart reflects the overall sentiment in the sector, reflecting investor skepticism toward new players in the highly competitive diabetes device market.
Shares shorted by the overall market
Beta Bionics is developing a "bionic pancreas"—a high-tech medical device. It's a classic growth story that requires investment. When this market pessimism indicator rises, investors flee unprofitable biotechs. They fear that during a recession, hospitals and patients will be unable to afford expensive innovations, delaying implementation.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Beta Bionics Inc (BBNX)
Beta Bionics (BBNX) is a medical device company that developed the iLet "bionic pancreas," an automated insulin delivery system for people with type 1 diabetes. This chart measures hype. It shows "overheated" (above 70) on news of FDA approval or "oversold" (below 30) amid concerns about competition or launch difficulties.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Beta-Bionics-Inc-BBNX&v=1772681280602 "RSI 14 indicator chart for the company's stock Beta Bionics Inc (BBNX)")
RSI 14 Market Segment - Specialized medical equipment
Beta Bionics (BBNX) is a medical device company developing the iLet, a fully automated insulin delivery system for diabetics. This chart tracks the pulse of the Specialty Medical Equipment sector. It helps differentiate BBNX's breakthrough technology from the generally overhyped or oversold diabetes sector.
RSI 14 for the overall market
Beta Bionics (BBNX), developer of the "bionic pancreas." This chart is its lifeline. Its business is pure R&D. During periods of euphoria, investors are willing to fund the "future of medicine." In moments of panic, they flee unprofitable R&D projects, and BBNX risks running out of funds for its breakthrough but expensive research.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BBNX (Beta Bionics Inc)
Beta Bionics is a medical device company that developed the iLet "bionic pancreas," an automated insulin delivery system that simplifies the management of type 1 diabetes. This chart shows the average price target from analysts, reflecting their expectations for the adoption of this new technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BBNX-Beta-Bionics-Inc&v=1772681280667 "A chart showing analyst consensus forecasts for the expected stock price. BBNX (Beta Bionics Inc)")
The difference between the consensus estimate and the actual stock price BBNX (Beta Bionics Inc)
Beta Bionics is a biotech company aiming to revolutionize the treatment of type 1 diabetes. Their flagship product is the iLet Bionic Pancreas, a fully automated artificial pancreas that automatically controls insulin delivery. This chart reflects analysts' high expectations for this breakthrough technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BBNX-Beta-Bionics-Inc&v=1772681280672 "A chart showing the difference between the consensus forecast and the actual stock price. BBNX (Beta Bionics Inc)")
Analyst consensus forecast for stock prices by market segment - Specialized medical equipment
Beta Bionics is a medical company that developed the iLet Bionic Pancreas, a smart insulin pump that fully automates insulin dosing for diabetics. This chart shows general expectations for the specialized medical equipment sector. It reflects whether experts believe the market for automated diabetes systems will boom.
Analysts' consensus forecast for the overall market share price
Beta Bionics is a medical device company that has developed the bionic pancreas (iLet), an automated insulin delivery system for people with type 1 diabetes. This chart shows the overall risk appetite. For Beta Bionics, a company with a revolutionary, life-changing product, overall market optimism is important for funding production and competing with medtech giants.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Beta Bionics Inc
Beta Bionics is a company at the forefront of type 1 diabetes treatment. They created the iLet—a bionic pancreas. It's a fully automated insulin delivery system that aims to make patients' lives as simple as possible by autonomously managing glucose levels. This chart evaluates their breakthrough technology, measuring the pace of commercial adoption of their system and their competition with the big guys.
AKIMA Market Segment Index - Specialized medical equipment
Beta Bionics (BBNX) is a diabetes medtech innovator; the company developed iLet, the world's first fully automated (bionic) insulin pump that makes decisions autonomously. This composite metric evaluates medtech companies. The graph shows the average value for the segment. This benchmark: how does this breakthrough (AI pump) technology (BBNX) differentiate it from the average competitor?
The AKIM Index for the overall market
Beta Bionics is a medical technology company that has developed a bionic pancreas (iLet) for automated diabetes management. This chart, which reflects the market average, provides context. It helps us assess how this innovative device commercialization story compares to the overall economic trends affecting medtech.
